Development of AI Model for Renal Tumor Diagnosis Using CT and Lab Tests
NCT ID: NCT06761742
Last Updated: 2025-01-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1922 participants
OBSERVATIONAL
2024-01-01
2024-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Optimising Renal Tumour Management Through Artificial Intelligence Modules
NCT06714916
Application of Radiomics-based AI Models in Predicting Clinical Outcome of Patients With Renal Cell Carcinoma After Surgical Treatment
NCT07118813
A Study Based on CT Radiomics for Distinguishing Benign From Malignant Renal Tumors and Assessing Their Aggressiveness.
NCT07060248
Development and Prospective Validation of a Digital Pathology-based Artificial Intelligence Diagnostic Model for Pan-cancer Lymphatic Metastasis
NCT06517979
Predicting HIF-2α Levels in Clear Cell Kidney Cancer Using Machine Learning
NCT07332923
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Training Set
No interventions assigned to this group
Validation Set
No interventions assigned to this group
Internal Test Set
No interventions assigned to this group
External Test Set
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Complete and available four-phase contrast-enhanced CT scans prior to surgery.
* Complete and available routine laboratory test results prior to surgery.
Exclusion Criteria
* A time interval of more than three months between imaging or laboratory testing and pathological diagnosis.
* Patients diagnosed with fat-rich renal angiomyolipoma (AML).
* Pathological diagnosis indicating the coexistence of two or more pathological types of renal tumors.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
OTHER
Fudan University Pudong Medical Center
UNKNOWN
Fudan University
OTHER
The Affiliated Hospital Of Southwest Medical University
OTHER
RenJi Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shanghai Jiaotong University School of Medicine, Renji Hospital
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DiagnosisModel_RenalTumor_AI
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.